Skip to main content
TipRanks
Go Ultimate75% OFF

INNOVATE Corp (PST0) Q3 2026 Earnings Report

0 Followers

DE:PST0 Q3 2026 EPS Results

Actual EPS
EUR 1.05
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-EUR 0.64

DE:PST0 Q3 2026 Revenue Results

Actual Revenue
EUR 449.49M
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
+42.75%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
DE:PST0 Upcoming Earnings

INNOVATE Corp's next earnings date is estimated for March 10, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:PST0 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call was predominantly positive, supported by 42.8% consolidated revenue growth, a return to net income, sharply higher adjusted EBITDA, strong DBMG operating results, completion of the DBMG sale, significant post-quarter debt reduction, and continued commercial and development progress at MediBeacon and R2. The company also reported lower Life Sciences revenue, weaker Spectrum results following the ownership disposition, industrial maintenance margin pressure, and higher indebtedness as of quarter end. Overall, the highlights significantly outweighed the lowlights.

Company Guidance

Management said initial Transdermal GFR use by big pharma in clinical trials is now anticipated in 2027; MediBeacon has secured orders for 600 TGFR Monitors, with shipments planned from the fourth quarter of 2026 through the second quarter of 2027, although conversion timing for new technology can take six to 12 months. R2 exited the quarter with 116 systems carrying into the fourth quarter, representing roughly $1.9 million of future revenue, with approximately 60 systems currently in production and delivery anticipated by November 30th. Following the DBMG sale, INNOVATE’s total principal indebtedness is now $238.3 million, which it expects to further reduce as it monetizes assets.

  • Strong Consolidated Revenue and Adjusted EBITDA GrowthThird-quarter consolidated revenue was $495.5 million, up 42.8% from $347.1 million in the prior-year period. Adjusted EBITDA was $40.5 million, up from $19.8 million, and net income attributable to common and participating preferred stockholders was $15.8 million, or $1.10 per fully diluted share, compared with a net loss of $9.4 million, or $0.71 per fully diluted share, in the prior-year period.
  • Completion of DBM Global Sale and Portfolio SimplificationINNOVATE completed the sale of DBM Global to IES Holdings on October 5, subsequent to quarter end. The transaction crystallized value created at DBMG, provided substantial liquidity, and left INNOVATE with an ownership interest in IES Holdings.
  • Exceptional DBM Global Operating PerformanceDBMG generated third-quarter revenue of $490.6 million and adjusted EBITDA of $43.6 million. Gross margin improved approximately 170 basis points year over year to 15.3%, while adjusted EBITDA margin improved approximately 200 basis points to 8.9%.
  • DBMG Backlog and Demand StrengthDBMG generated approximately $500 million of revenue from existing backlog while maintaining adjusted backlog at approximately $2.7 billion. Sales activity remained healthy across contracted awards, negotiated work, and project scope expansion, with technology, healthcare, and New York City identified as key areas of activity.
  • DBMG Strong Position at ClosingDBMG ended its final quarter under INNOVATE's ownership with September 30, 2026, LTM adjusted EBITDA of $143.3 million, substantial backlog, and a healthy pipeline of opportunities extending into 2027 and 2028.
  • Infrastructure Segment Revenue and EBITDA GrowthInfrastructure revenue increased 45% to $490.6 million from $338.4 million in the prior-year quarter. Infrastructure adjusted EBITDA increased to $43.6 million from $23.5 million, driven primarily by higher activity and project efficiencies at DBMG's commercial structural steel business.
  • Infrastructure Backlog Expansion and Debt ReductionAs of September 30, 2026, reported backlog was $2.6 billion and adjusted backlog was $2.7 billion, compared with $1.7 billion and $1.8 billion, respectively, at the end of 2025. DBMG's principal debt declined by $19 million from year-end 2025 to $68.7 million, and its debt was repaid in full at the closing of the sale.
  • MediBeacon Commercial and Reimbursement ProgressMediBeacon advanced commercialization of the TGFR System, with product shipments, research activities, and clinical utilization underway at leading medical centers. The company continued engagement with the Centers for Medicare & Medicaid Services and key private payers for additional reimbursement coding, while expanding engagement with key opinion leaders and hospital value analysis committees.
  • MediBeacon Recognition and Product DevelopmentMediBeacon's TGFR System was nominated for the 2026 Prix Galien USA Best Medical Technology Award. Its third-generation wireless TGFR Sensor received FDA investigational device exemption approval authorizing the start of validation studies in the United States.
  • MediBeacon International and Pharmaceutical OpportunityMediBeacon secured orders for 600 TGFR Monitors in China, with shipments planned from the fourth quarter of 2026 through the second quarter of 2027. Interest from pharmaceutical and biotechnology customers continued to grow, and initial Transdermal GFR use by big pharma in clinical trials is anticipated in 2027.
  • R2 Demand and Manufacturing ExpansionR2 reported worldwide demand of 3.1 million and exited the quarter with 116 systems carrying into the fourth quarter, representing roughly $1.9 million of future revenue. Production of Glacial fx at EIT is now underway, with 30 systems delivered and approximately 60 in production, with delivery anticipated by November 30.
  • Broadcasting Asset Monetization and Continued ParticipationINNOVATE completed the sale of a controlling interest in broadcasting to CONX Corp. while retaining a 25% ownership interest and an option to acquire up to an additional 15%, potentially reaching a 40% ownership stake. Broadcasting had 287 operating stations and continued pursuing station acquisitions, FCC license opportunities, and opportunities beyond traditional linear broadcasting.
  • Debt Reduction Following DBMG SaleINNOVATE received approximately $413 million in cash at the closing of the DBMG sale and used net proceeds to repay its corporate credit line and redeem $325 million of senior secured notes. Total principal indebtedness declined to $238.3 million after the repayments, and the company expects to reduce it further as assets are monetized.
  • Potential BeneVir Milestone Payments and Genovel OwnershipThrough Pansend, INNOVATE remains eligible for potential milestone payments of up to $900 million in aggregate related to the 2018 sale of BeneVir Biopharm, including up to $500 million due to INNOVATE, subject to specified regulatory approvals and net sales thresholds. Pansend also owns 80% of Genovel Orthopedics.
  • Improved Corporate Adjusted EBITDA LossNon-operating corporate adjusted EBITDA loss improved by $400,000 year over year, primarily due to a decrease in professional fees.

DE:PST0 Earnings History

DE:PST0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 10, 20272026 (Q4)―--0.53――
Nov 12, 20262026 (Q3)―1.05-0.64262.62% (+1.69)
Aug 06, 20262026 (Q2)―0.68-1.52144.53% (+2.19)
May 14, 20262026 (Q1)―-1.17-1.7231.84% (+0.55)
Mar 26, 20262025 (Q4)―-0.53-1.1754.72% (+0.64)
Nov 12, 20252025 (Q3)―-0.64-1.0739.92% (+0.43)
Aug 05, 20252025 (Q2)―-1.520.89-271.24% (-2.40)
May 06, 20252025 (Q1)―-1.71-2.0415.96% (+0.33)
Mar 31, 20252024 (Q4)―-1.72-2.0415.92% (+0.32)
Nov 06, 20242024 (Q3)―-1.07-0.84-27.71% (-0.23)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed